High materiality9/10
Viridian Therapeutics price target raised to $38 from $36 at RBC Capital
Why it may matterVerify against the original reporting
very_bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
RBC Capital raises VRDN target to $38 from $36. Current price is $21.58. Price change since signal: +2.27. The setup points to meaningful upside.
- Target up to 38; price 21.58; upside
Key facts
- 01
Target: $38
- 02
Posted price: $21.58
- 03
Analyst firm: RBC Capital
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.